Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Human trials to begin for Humanetics Alzheimer’s drug
Phase I and phase II studies of the compound, NIC5-15, in a population of early stage Alzheimer’s disease patients will now be immediately advanced by Mount Sinai School
Phase I and phase II studies of the compound, NIC5-15, in a population of early stage Alzheimer’s disease patients will now be immediately advanced by Mount Sinai School
GSK, through its recently established Center of Excellence for External Drug Discovery (CEEDD), and Pharmacopeia will collaborate to deliver clinically validated therapeutic candidates to GSK’s global R&D organization.
The Phoenix facility currently manufactures fifteen products, including several manufactured for third parties. Over the next twelve months, the company plans to establish contract manufacturing agreements for key
Nexavar (sorafenib) tablets will be indicated for the treatment of patients with advanced renal cell carcinoma (RCC), or kidney cancer, after nepherectomy and prior palliative or adjuvant therapy
Through its manufacturing subsidiary, Teamm Pharmaceuticals, Accentia will now be able to produce a new dosage of Xodol (hydrocodone bitartrate and acetaminophen tablets, USP), giving physicians additional choices
The submission to the FDA is based on existing clinical data and new studies recently completed by Pharmion. Vidaza was approved by the FDA in 2004 for the
Patients who previously participated in the phase III MS trials and subsequent safety evaluation are eligible to be screened for entry in this open label multi-center study. Sites
Galvus, a DPP-4 inhibitor, works through a novel mechanism of action targeting the pancreatic islet dysfunction that causes high blood sugar levels in people with type 2 diabetes.
Arthrogen was founded in 2005 as a joint venture between the Dubai Bone & Joint Center (DBAJ) in the United Arab Emirates and the Academic Medical Center (AMC)
The deal will combine the strengths of the two generics companies and will allow Ranbaxy to leverage its expanded base in the rapidly growing Romanian pharmaceutical market, across